azd5312
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02144051)
Timeline
Indications
Mechanism of action
- Androgen ReceptorINHIBITOR
Androgen Receptor inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- azd5312
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03300505 | Phase 2 | Oct 31, 2018 | University of Michigan |
| NCT02144051 | Phase 1 | May 1, 2014 | AstraZeneca, SCRI Development Innovations |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2014 |
| SCRI Development Innovations | For profit | 1 | 0 | 1 | 2014 |
| University of Michigan | Academic/Hospital | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1